XRP (XRP) price is showing early signs of a potential bottom after forming a swing failure pattern (SFP) around the $1.80 level.XRP (XRP) price is showing early signs of a potential bottom after forming a swing failure pattern (SFP) around the $1.80 level.

XRP price forms a swing failure, signaling a potential bottom

XRP price prints a swing failure pattern at $1.80 and reclaims support, suggesting downside exhaustion as traders watch the $1.98 level for bullish confirmation.

Summary
  • The swing failure pattern forms at $1.80, suggesting a local bottom.
  • Price remains below the $1.98 Point of Control resistance.
  • Reclaiming $1.98 could open a move toward $2.20.

XRP (XRP) price is showing early signs of a potential bottom after forming a swing failure pattern (SFP) around the $1.80 level. This pattern, often associated with downside exhaustion, has emerged as the price reclaimed the $1.80 region after briefly trading below it.

While confirmation is still pending, the structure suggests that selling pressure may be weakening, opening the door for a short-term bullish recovery if key resistance levels are reclaimed.

XRP price key technical points

  • Swing failure pattern forms at $1.80, signaling possible downside exhaustion.
  • Price trades below the Point of Control at $1.98, which remains the key resistance to reclaim.
  • Holding the 0.618 Fibonacci retracement could confirm the bullish setup.
XRP price forms a swing failure, signaling a potential bottom - 1

The swing failure pattern at $1.80 is technically significant because it reflects a failed attempt by sellers to sustain price below a key support level. In an SFP, price briefly breaks below support, triggers liquidity, and then quickly reclaims the level, trapping late sellers. This behavior often marks local bottoms, especially when it occurs after an extended decline.

In XRP’s case, the reclaim of $1.80 suggests that buyers are actively defending this region. However, price has since moved lower after rejecting from the Point of Control (POC) near $1.98, a level that represents the highest traded volume within the current range. This rejection indicates that while downside pressure may be easing, bulls have not yet regained control, even as XRP-linked ETF assets climb past $60 million despite ongoing weakness in the token’s spot price.

The current pullback toward the 0.618 Fibonacci retracement is a critical test for the bullish thesis. This level often serves as a key support during corrective phases in the development of reversals. If price holds this region and forms higher lows, it would add further confirmation to the swing failure pattern and strengthen the probability of continuation higher.

From a market-structure perspective, XRP remains in a transitional phase. While the swing failure pattern suggests a potential shift in momentum, the broader structure has not yet flipped decisively bullish. Price is still trading below the POC and below the Value Area Low, which means acceptance back into higher value has not been achieved.

One level to watch remains $1.98. This region serves as both the POC and a high-time-frame resistance. A clean reclaim of $1.98 on a closing basis would signal acceptance of value and confirm the swing failure pattern as a valid bottoming structure. Such a move would likely open the path for a rally toward the $2.20 resistance, where prior selling pressure has previously emerged.

Until that reclaim occurs, caution is warranted. Failed swing failure patterns can lead to renewed downside if buyers fail to follow through. This is why holding above $1.80 and defending the 0.618 Fibonacci level is essential for maintaining bullish momentum.

Volume behavior will also be a key confirmation factor. A successful breakout above $1.98 should be accompanied by increased volume, signaling genuine demand rather than a short-lived relief bounce. Without this, any upside movement risks being corrective rather than impulsive.

In summary, XRP’s price action reflects a market at an inflection point. The swing failure pattern at $1.80 offers a constructive signal, but confirmation remains dependent on how price behaves around key volume and resistance levels.

What to expect in the coming price action

If XRP holds above the 0.618 Fibonacci level and reclaims the $1.98 Point of Control, the probability of a bullish continuation toward $2.20 increases. Failure to reclaim this region would keep price rotational and warrant continued caution.

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.9101
$1.9101$1.9101
-0.21%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26